We are live on
!
Find out more
MRCM
M&R Capital Management Portfolio holdings
AUM
$454M
1-Year Est. Return
40.11%
This Fund
S&P 500
This Quarter
Est. Return
+1.51%
1 Year Est. Return
+40.11%
3 Year Est. Return
+52.56%
5 Year Est. Return
+141.03%
10 Year Est. Return
+275.44%
AUM
$414M
AUM Growth
+$32.3M
(+8.5%)
Cap. Flow
+$27.9M
Cap. Flow
% of AUM
6.73%
Top 10 Holdings %
Top 10 Hldgs %
30.48%
Holding
216
New
11
Increased
89
Reduced
59
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$8.36M |
| 2 |
NOV
NOV
|
+$1.18M |
| 3 |
GNC
GNC Holdings, Inc.
GNC
|
+$936K |
| 4 |
Visa
V
|
+$812K |
| 5 |
ESRX
Express Scripts Holding Company
ESRX
|
+$805K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Philip Morris
PM
|
+$501K |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$380K |
| 3 |
PCL
PLUM CREEK TIMBER CO (REIT)
PCL
|
+$326K |
| 4 |
Liberty Global Class A
LBTYA
|
+$282K |
| 5 |
Biogen
BIIB
|
+$280K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.03% |
| 2 | Miscellaneous | 15.33% |
| 3 | Financials | 12.38% |
| 4 | Industrials | 11.36% |
| 5 | Technology | 10.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Alphabet (Google) Class C
GOOG
$4.19T
| $14M | 3.37% |
503,520
+17,264
| +4% | +$503K |
|
|
DTV
2
DELISTED
DIRECTV COM STK (DE)
DTV
| $13.9M | 3.36% |
182,241
+9,775
| +6% | +$717K |
|
3
Comcast
CMCSA
$96B
| $12.8M | 3.1% |
513,404
+26,208
| +5% | +$683K |
|
4
Bausch Health
BHC
$2.36B
| $12.1M | 2.92% |
91,908
+5,623
| +7% | +$769K |
|
5
Qualcomm
QCOM
$175B
| $11.8M | 2.84% |
149,314
+9,685
| +7% | +$729K |
|
|
6
Visa
V
$712B
| $11.6M | 2.8% |
215,268
+14,604
| +7% | +$812K |
|
|
ESRX
7
DELISTED
Express Scripts Holding Company
ESRX
| $11.5M | 2.77% |
152,768
+10,754
| +8% | +$805K |
|
8
Norfolk Southern
NSC
$78.3B
| $11.4M | 2.74% |
116,841
+4,313
| +4% | +$400K |
|
|
TFCFA
9
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
| $9.92M | 2.39% |
310,219
+21,650
| +8% | +$708K |
|
|
10
NOV
NOV
$7.48B
| $9.79M | 2.36% |
139,417
+17,255
| +14% | +$1.18M |
|
|
COV
11
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $9.48M | 2.29% |
128,761
+9,802
| +8% | +$684K |
|
|
AGN
12
DELISTED
Allergan plc
AGN
| $9.16M | 2.21% |
44,505
+42,207
| +1,837% | +$8.36M |
|
13
ExxonMobil
XOM
$644B
| $8.95M | 2.16% |
91,572
-782
| -0.8% | -$74.5K |
|
|
BNY
14
Bank of New York Mellon
BNY
$110B
| $8.76M | 2.11% |
248,329
+17,709
| +8% | +$585K |
|
15
Toronto Dominion Bank
TD
$199B
| $8.43M | 2.03% |
179,444
+14,190
| +9% | +$640K |
|
16
CSX Corp
CSX
$95B
| $8.38M | 2.02% |
867,759
+80,280
| +10% | +$745K |
|
17
FedEx
FDX
$78.3B
| $8.29M | 2% |
62,513
+3,847
| +7% | +$522K |
|
18
Aflac
AFL
$58.4B
| $7.52M | 1.81% |
238,560
+20,568
| +9% | +$654K |
|
|
GNC
19
DELISTED
GNC Holdings, Inc.
GNC
| $7.41M | 1.79% |
168,330
+18,914
| +13% | +$936K |
|
20
Johnson & Johnson
JNJ
$646B
| $6.93M | 1.67% |
70,571
-581
| -0.8% | -$53.9K |
|
21
Accenture
ACN
$116B
| $6.43M | 1.55% |
80,679
+7,430
| +10% | +$610K |
|
22
Sabesp
SBS
$17.1B
| $5.75M | 1.39% |
3,202,252
+268,165
| +9% | +$488K |
|
23
Healthpeak Properties
DOC
$14.5B
| $5.66M | 1.37% |
160,233
+16,646
| +12% | +$575K |
|
24
PepsiCo
PEP
$193B
| $5.57M | 1.34% |
66,704
-22
| -0% | -$1.79K |
|
25
IBM
IBM
$222B
| $5.47M | 1.32% |
29,737
+3,933
| +15% | +$692K |
|
Similar funds
EDRIA
SFP
AC
NIC
WCA
KC
SIGI
FPFS
M&R Capital Management's Q1 2014 Portfolio in Review
As of Q1 2014, M&R Capital Management held 216 positions worth $414M, up 8.5% from $382M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
M&R Capital Management deployed $27.9M of net new capital in Q1 2014, opening 11 new positions and adding to 89 existing holdings. Its largest new stake was Magellan Midstream Partners, L.P.: 5,800 shares worth $404K.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 15% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Philip Morris, an estimated $501K trimmed.
- M&R Capital Management's largest Q1 2014 buy was Magellan Midstream Partners, L.P.: 5,800 shares worth $404K.
- M&R Capital Management added most to Allergan plc in Q1 2014, an estimated $8.36M increase.
- M&R Capital Management's biggest Q1 2014 reduction was Philip Morris, cutting an estimated $501K.
- M&R Capital Management fully exited Teva Pharmaceuticals in Q1 2014, selling an estimated $380K.
- M&R Capital Management's ten largest holdings make up 30% of its $414M portfolio in Q1 2014.
- M&R Capital Management opened 11 new positions and closed 8 in Q1 2014.
- M&R Capital Management's portfolio value rose 8.5% quarter-over-quarter to $414M.
Based on M&R Capital Management's 13F filing for Q1 2014, filed 2 May 2014.